Literature DB >> 20142621

Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis.

S Gutwinski1, S Erbe, C Münch, O Janke, U Müller, J Haas.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20142621     DOI： 10.1212/WNL.0b013e3181cef810

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  7 in total

1.  Fungal immunology in clinical practice: Magical realism or practical reality?

Authors:  Christina C Chang; Stuart M Levitz
Journal:  Med Mycol       Date:  2019-06-01       Impact factor: 4.076

Review 2.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 3.  Infectious Complications of Novel Multiple Sclerosis Therapies.

Authors:  S N Levin; T B Kaplan
Journal:  Curr Infect Dis Rep       Date:  2017-02       Impact factor: 3.725

4.  Fungal infection in cerebrospinal fluid from some patients with multiple sclerosis.

Authors:  D Pisa; R Alonso; F J Jiménez-Jiménez; L Carrasco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-16       Impact factor: 3.267

Review 5.  Natalizumab therapy for multiple sclerosis.

Authors:  Jeremy Chataway; David H Miller
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 6.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

Review 7.  A Fungal World: Could the Gut Mycobiome Be Involved in Neurological Disease?

Authors:  Jessica D Forbes; Charles N Bernstein; Helen Tremlett; Gary Van Domselaar; Natalie C Knox
Journal:  Front Microbiol       Date:  2019-01-09       Impact factor: 5.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.